Compare AU
Compare CURE vs. GCAP
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and GCAP. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
CURE | GCAP | |
|---|---|---|
Popularity | Low | N/A |
Pearlers invested | 82 | 0 |
Median incremental investment | $619.50 | $0 |
Median investment frequency | Monthly | N/A |
Median total investment | $1,323.41 | $0 |
Average age group | > 35 | N/A |
Key Summary
CURE | GCAP | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | GCAP.AX was created on 2021-08-03 by VanEck. The fund's investment portfolio concentrates primarily on investment grade fixed income. GCAP.AX aims to provide investors with a professionally managed active strategy in global Capital Securities. The fund aims to provide total investment returns, measured over the long term in excess of the Benchmark. |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | VanEck Bentham Gl Cap Se Active ETF (Managed Fund) (100 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 0.59 % |
Key Summary
CURE | GCAP | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.59 % |
Price | $49.94 | $8.85 |
Size | $38.065 million | $28.631 million |
10Y return | N/A | N/A |
Annual distribution/ dividend yield (5Y) | 4.24 % | 3.42 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 04/08/2021 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | GCAP | |
|---|---|---|
Popularity | Low | N/A |
Pearlers invested | 82 | 0 |
Median incremental investment | $619.50 | $0 |
Median investment frequency | Monthly | N/A |
Median total investment | $1,323.41 | $0 |
Average age group | > 35 | N/A |
Pros and Cons
CURE | GCAP | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | GCAP |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |